Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-demethylnobiletin is a naturally occurring polymethoxyflavone, primarily found in citrus fruits, especially in their peels and as a metabolite of nobiletin formed during storage. It exhibits a range of **pharmacological activities**, including anti-inflammatory, anticancer, antioxidant, and neuroprotective effects. Mechanistically, 5-demethylnobiletin acts through regulation of multiple signaling pathways, including direct inhibition of 5-lipoxygenase (5-LOX), and modulation of MAPK/ERK, PKC, PKA, JAK2/STAT3, ROS-AKT/mTOR, and caspase-dependent apoptosis pathways. It induces cell cycle arrest and apoptosis in tumor cells (notably glioblastoma), suppresses inflammation by inhibiting iNOS and COX-2 expression, and has demonstrated activity against various cancers and inflammation-related diseases. Its metabolites often show stronger biological activities than the parent compound[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-demethylnobiletin.